Literature DB >> 27022951

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells.

Ashley Ulm1, Christopher N Mayhew2, Jason Debley3, Gurjit K Khurana Hershey4, Hong Ji5.   

Abstract

Nasal epithelial cells (NECs) are the part of the airways that respond to air pollutants and are the first cells infected with respiratory viruses. They are also involved in many airway diseases through their innate immune response and interaction with immune and airway stromal cells. NECs are of particular interest for studies in children due to their accessibility during clinical visits. Human induced pluripotent stem cells (iPSCs) have been generated from multiple cell types and are a powerful tool for modeling human development and disease, as well as for their potential applications in regenerative medicine. This is the first protocol to lay out methods for successful generation of iPSCs from NECs derived from pediatric participants for research purposes. It describes how to obtain nasal epithelial cells from children, how to generate primary NEC cultures from these samples, and how to reprogram primary NECs into well-characterized iPSCs. Nasal mucosa samples are useful in epidemiological studies related to the effects of air pollution in children, and provide an important tool for studying airway disease. Primary nasal cells and iPSCs derived from them can be a tool for providing unlimited material for patient-specific research in diverse areas of airway epithelial biology, including asthma and COPD research.

Entities:  

Mesh:

Year:  2016        PMID: 27022951      PMCID: PMC4792220          DOI: 10.3791/53814

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  43 in total

1.  Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming.

Authors:  Eva Warlich; Johannes Kuehle; Tobias Cantz; Martijn H Brugman; Tobias Maetzig; Melanie Galla; Adam A Filipczyk; Stephan Halle; Hannes Klump; Hans R Schöler; Christopher Baum; Timm Schroeder; Axel Schambach
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

2.  A more efficient method to generate integration-free human iPS cells.

Authors:  Keisuke Okita; Yasuko Matsumura; Yoshiko Sato; Aki Okada; Asuka Morizane; Satoshi Okamoto; Hyenjong Hong; Masato Nakagawa; Koji Tanabe; Ken-ichi Tezuka; Toshiyuki Shibata; Takahiro Kunisada; Masayo Takahashi; Jun Takahashi; Hiroh Saji; Shinya Yamanaka
Journal:  Nat Methods       Date:  2011-04-03       Impact factor: 28.547

3.  Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts.

Authors:  Akiko Doi; In-Hyun Park; Bo Wen; Peter Murakami; Martin J Aryee; Rafael Irizarry; Brian Herb; Christine Ladd-Acosta; Junsung Rho; Sabine Loewer; Justine Miller; Thorsten Schlaeger; George Q Daley; Andrew P Feinberg
Journal:  Nat Genet       Date:  2009-11-01       Impact factor: 38.330

Review 4.  The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium.

Authors:  Jack R Harkema; Stephan A Carey; James G Wagner
Journal:  Toxicol Pathol       Date:  2006       Impact factor: 1.902

5.  Induced pluripotent stem cells generated without viral integration.

Authors:  Matthias Stadtfeld; Masaki Nagaya; Jochen Utikal; Gordon Weir; Konrad Hochedlinger
Journal:  Science       Date:  2008-09-25       Impact factor: 47.728

6.  Embryonic stem cell lines derived from human blastocysts.

Authors:  J A Thomson; J Itskovitz-Eldor; S S Shapiro; M A Waknitz; J J Swiergiel; V S Marshall; J M Jones
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

7.  Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease.

Authors:  Alex Poole; Cydney Urbanek; Celeste Eng; Jeoffrey Schageman; Sean Jacobson; Brian P O'Connor; Joshua M Galanter; Christopher R Gignoux; Lindsey A Roth; Rajesh Kumar; Sharon Lutz; Andrew H Liu; Tasha E Fingerlin; Robert A Setterquist; Esteban G Burchard; Jose Rodriguez-Santana; Max A Seibold
Journal:  J Allergy Clin Immunol       Date:  2014-02-02       Impact factor: 10.793

8.  Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome.

Authors:  Sergiu P Paşca; Thomas Portmann; Irina Voineagu; Masayuki Yazawa; Aleksandr Shcheglovitov; Anca M Paşca; Branden Cord; Theo D Palmer; Sachiko Chikahisa; Seiji Nishino; Jonathan A Bernstein; Joachim Hallmayer; Daniel H Geschwind; Ricardo E Dolmetsch
Journal:  Nat Med       Date:  2011-11-27       Impact factor: 53.440

9.  Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds.

Authors:  Danwei Huangfu; René Maehr; Wenjun Guo; Astrid Eijkelenboom; Melinda Snitow; Alice E Chen; Douglas A Melton
Journal:  Nat Biotechnol       Date:  2008-06-22       Impact factor: 54.908

10.  Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein.

Authors:  Amy P Wong; Christine E Bear; Stephanie Chin; Peter Pasceri; Tadeo O Thompson; Ling-Jun Huan; Felix Ratjen; James Ellis; Janet Rossant
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

View more
  2 in total

1.  Increased nasal epithelial cell responsiveness to IL-17A in paediatric asthmatics with low blood neutrophil count, low traffic-related air pollution exposure and good asthma control.

Authors:  Jaclyn W McAlees; Theresa Baker; Lauren Houshel; Christopher McKnight; Andrew Lindsley; Richard T Strait; Xue Zhang; Angela Cannata; Jocelyn M Biagini; Melinda Butsch Kovacic; Ian P Lewkowich
Journal:  Clin Exp Allergy       Date:  2021-12-27       Impact factor: 5.018

2.  Prioritizing chronic obstructive pulmonary disease (COPD) candidate genes in COPD-related networks.

Authors:  Yihua Zhang; Wan Li; Yuyan Feng; Shanshan Guo; Xilei Zhao; Yahui Wang; Yuehan He; Weiming He; Lina Chen
Journal:  Oncotarget       Date:  2017-10-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.